Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
Figure 5
Serum IGFBP3 levels before EGFR-TKI treatment and after the development of resistance.
IGFBP-3 levels were determined by ELISA in the serum of patients with NSCLC. Acquired resistance developed in all patients who initially responded to EGFR-TKIs.